ClinicalTrials.gg
CompletedNCT02006472Updated Jul 19, 2021Results posted

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

A Phase 2 interventional study of Pridopidine and Placebo in Huntington's Disease, sponsored by Prilenia. Completed at 58 sites in 12 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-07-19.

Sponsored by Prilenia · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Enrollment
6th of 90
408 · median 44
Started
2014
with 3 others
Phase 2
28 of 138
none open now
Registered
58th of 138
by date
Lead sponsor
4 of 138
Prilenia

Among the 138 studies in Huntington Disease with a site in United States, this one is the 6th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2014, is one of 28 in phase 2, and was the 58th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).

Read the detailed description

Originally, the study was designed to assess the effect of pridopidine on motor function at 26 weeks. Due to the recognition that the primary target of pridopidine is the Sigma-1 receptor, the trial was extended from 26 to 52 weeks to evaluate the effect of pridopidine on Total Functional Capacity (TFC). A minimum of 52 weeks are needed for the placebo group to decline and allow a window to assess an effect on TFC (a prespecified endpoint). Approximately 20% of patients completed 26 weeks of the study before IRB approvals for this extension, and did not continue into the 2nd treatment period up to 52 weeks.

03

Conditions studied

  • Huntington's Disease

Browse trials for

Keywords

  • Huntington's Disease
  • Pridopidine
  • Pride-HD
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HD based on the presence of >/= 36 CAG repeats
  • Male or female age ≥21 years, with an onset of HD after 18 years' old.
  • Females of must be compliant in using adequate throughout the duration of the study
  • Body weight ≥50 kg
  • Sum of >= 25 points on the UHDRS-TMS and UHDRS Independence Score \<=90%
  • Able and willing to provide written prior to any study related procedure.
  • Willing to provide a blood sample for genetic analyses
  • Willing and able to take oral medication and able to comply with the study specific procedures.
  • Ambulatory, being able to travel to the study center, and judged by the investigator as likely to be able to continue to travel for the duration of the study.
  • Availability and willingness of a caregiver, informant or family member to accompany the patient to the clinic at study, and the suitability of the caregiver should be judged by the Investigator.

    • Other criteria apply, please contact the investigator for more information.

Exclusion criteria

Exclusion Criteria:

  • Patients with heart disease at the screening visit
  • Treatment with tetrabenazine within 6 weeks of study screening
  • Patients with a history of epilepsy or of seizures within the last 5 years
  • Have other serious medical illnesses in the opinion of the investigator may put the patient at risk when participating in the study or may influence the results of the study or affect the patient's ability to take part in the study
  • Patients receiving medications (within the last 6 weeks prior to screening) that have been proven to prolong or who may require such medications during the course of the study such as but not limited to non allowed anti psychotic medications, tricyclic antidepressants and/or Class I antiarrhythmics

    • Other criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    Pridopidine 45 mg

    Twice daily

    Drug: Pridopidine · Other: Placebo

  • Experimental
    Pridopidine 67.5 mg

    Twice daily

    Drug: Pridopidine · Other: Placebo

  • Experimental
    Pridopidine 90 mg

    Twice daily

    Drug: Pridopidine · Other: Placebo

  • Experimental
    Pridopidine 112.5 mg

    Twice daily

    Drug: Pridopidine · Other: Placebo

  • Placebo comparator
    Placebo

    Twice daily

    Other: Placebo

Interventions

  • 22.5 mg and 45 mg capsules

    Also known as: TV7820

  • OtherPlacebo

    Capsules matching drug

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26

    TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.

    Time frame: 26 weeks

Secondary outcomes

  1. Number of Patients With Adverse Events

    Time frame: 52 weeks

Other outcomes

  1. Change From Baseline in Total Functional Capacity (TFC) at Week 52

    The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.

    Time frame: 52 weeks

07

Results

Posted Jul 19, 2021
Limitations and caveats
Analyses for Early HD population were conducted as additional analyses

Participant flow

Period 1 (Through Week 26)
Participant flow — Period 1 (Through Week 26)
MilestonePlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BID
Started8281828182
Itt8281828182
Fas8175798181
Safety set8281828182
Completed7059656762
Not completed1222171420
Withdrew: Protocol violation11110
Withdrew: Lack of efficacy00100
Withdrew: Noncompliance21100
Withdrew: Other15023
Withdrew: Adverse event56111114
Withdrew: Withdrawal by subject39303
Period 2 (Through Week 52)
Participant flow — Period 2 (Through Week 52)
MilestonePlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BID
Started5749545646
Started treatment in period 25749525646
Completed5243445344
Not completed561032
Withdrew: Lack of efficacy10011
Withdrew: Noncompliance10000
Withdrew: Adverse event14511
Withdrew: Other01010
Withdrew: Not treated00200
Withdrew: Withdrawal by subject21200
Withdrew: Sponsor decision00100

Outcome measures

PrimaryChange From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26

TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.

Time frame:
26 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26
score on a scalePlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BID
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26-4.79 ± 0.99-3.37 ± 1.05-3.09 ± 1.02-4.13 ± 1.00-2.74 ± 1.01
Statistical analysis
  • Placebo vs Pridopidine 45 mg BID · Mixed Models Analysis · p = 0.3202 · Lsm difference: 1.42 · 95% CI -1.39 to 4.23
  • Placebo vs Pridopidine 67.5 mg BID · Mixed Models Analysis · p = 0.2266 · Lsm difference: 1.7 · 95% CI -1.06 to 4.46
  • Placebo vs Pridopidine 90 mg BID · Mixed Models Analysis · p = 0.6348 · Lsm difference: 0.66 · 95% CI -2.07 to 3.39
  • Placebo vs Pridopidine 112.5 mg BID · Mixed Models Analysis · p = 0.1447 · Lsm difference: 2.04 · 95% CI -0.71 to 4.8
SecondaryNumber of Patients With Adverse Events
Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events
ParticipantsPlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BID
Number of Patients With Adverse Events6263697167
Other pre-specifiedChange From Baseline in Total Functional Capacity (TFC) at Week 52

The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.

Time frame:
52 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Total Functional Capacity (TFC) at Week 52
score on a scalePlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BID
Change From Baseline in Total Functional Capacity (TFC) at Week 52-0.83 ± 0.200.04 ± 0.22-0.72 ± 0.21-0.65 ± 0.20-0.59 ± 0.22
Statistical analysis
  • Placebo vs Pridopidine 45 mg BID · Mixed Models Analysis · p = 0.0032 · Lsm difference: 0.87 · 95% CI 0.29 to 1.45
  • Placebo vs Pridopidine 67.5 mg BID · Mixed Models Analysis · p = 0.7042 · Lsm difference: 0.11 · 95% CI -0.46 to 0.68
  • Placebo vs Pridopidine 90 mg BID · Mixed Models Analysis · p = 0.5099 · Lsm difference: 0.19 · 95% CI -0.37 to 0.75
  • Placebo vs Pridopidine 112.5 mg BID · Mixed Models Analysis · p = 0.4061 · Lsm difference: 0.24 · 95% CI -0.33 to 0.82
Post-hocChange in Total Functional Capacity (TFC) From Baseline in Patients With Early HD (Defined as Patients With TFC>=7)

The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.

Time frame:
52 weeks
Reported as:
Least squares mean · score on a scale
Change in Total Functional Capacity (TFC) From Baseline in Patients With Early HD (Defined as Patients With TFC>=7)
score on a scalePlaceboPridopidine 45 mg BID
Change in Total Functional Capacity (TFC) From Baseline in Patients With Early HD (Defined as Patients With TFC>=7)-1.17 ± 0.22-0.01 ± 0.23
Statistical analysis
  • Placebo vs Pridopidine 45 mg BID · Mixed Models Analysis · p = 0.0003 · Lsm difference: 1.16 · 95% CI 0.54 to 1.78
Post-hocTotal Functional Capacity Responder Rate in Early HD

The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Responder was defined as a TFC change to Week 52 of TFC\>=0.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Total Functional Capacity Responder Rate in Early HD
ParticipantsPlaceboPridopidine 45 mg BID
Total Functional Capacity Responder Rate in Early HD2030
Statistical analysis
  • Placebo vs Pridopidine 45 mg BID · Chi-squared · p = 0.003
Post-hocChange From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Tap-interval-MN-Hand, Early HD

Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Tap-interval-MN-Hand, measured in seconds. Positive change from baseline indicates worsening.

Time frame:
26 and 52 weeks
Reported as:
Least squares mean · seconds
Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Tap-interval-MN-Hand, Early HD
secondsPlaceboPridopidine 45 mg BID
Change from baseline to Week 260.0247 ± 0.0118-0.0096 ± 0.0110
Change from baseline to Week 520.0447 ± 0.01420.0003 ± 0.0150
Statistical analysis
  • Placebo vs Pridopidine 45 mg BID · Mixed Models Analysis · p = 0.0346 · Lsm difference: -0.0341 · 95% CI -0.0658 to -0.0026
  • Placebo vs Pridopidine 45 mg BID · Mixed Models Analysis · p = 0.0305 · Lsm difference: -0.0444 · 95% CI -0.0847 to -0.0042

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/82 (0%)0/82 (0%)45/82 (54.9%)
Pridopidine 45 mg BID0/81 (0%)8/81 (9.9%)49/81 (60.5%)
Pridopidine 67.5 mg BID0/82 (0%)9/82 (11%)63/82 (76.8%)
Pridopidine 90 mg BID1/81 (1.2%)9/81 (11.1%)57/81 (70.4%)
Pridopidine 112.5 mg BID1/82 (1.2%)9/82 (11%)53/82 (64.6%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BID
FallInjury, poisoning and procedural complications0/824/810/821/810/82
Head injuryInjury, poisoning and procedural complications0/822/810/820/811/82
Suicide attemptPsychiatric disorders0/821/810/821/812/82
LacerationInjury, poisoning and procedural complications0/821/810/820/810/82
Humerus fractureInjury, poisoning and procedural complications0/821/810/820/810/82
Hand fractureInjury, poisoning and procedural complications0/821/810/820/810/82
ConcussionInjury, poisoning and procedural complications0/821/810/820/810/82
Skull fractureInjury, poisoning and procedural complications0/821/810/820/810/82
Blood creatine phosphokinase increasedInvestigations0/821/810/820/810/82
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/821/810/820/810/82
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BID
FallInjury, poisoning and procedural complications17/8216/8121/8213/8116/82
NasopharyngitisInfections and infestations7/8214/8112/8213/8115/82
ChoreaNervous system disorders1/824/8113/823/817/82
HeadacheNervous system disorders8/827/817/8211/818/82
DiarrhoeaGastrointestinal disorders9/829/8111/8211/8110/82
InsomniaPsychiatric disorders3/825/8111/829/819/82
FatigueGeneral disorders7/823/816/827/815/82
AnxietyPsychiatric disorders2/826/816/827/815/82
Weight decreasedInvestigations3/824/813/823/817/82
Suicidal ideationPsychiatric disorders0/822/817/821/810/82

Baseline characteristics

Intent-to-treat: all patients randomized into the study

Age, Continuous
Age, Continuous(years)PlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BIDTotal
Mean50.3 ± 11.3451.9 ± 11.7551.0 ± 11.8351.3 ± 12.6947.5 ± 11.4050.4 ± 11.85
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BIDTotal
Female4040414339203
Male4241413843205
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BIDTotal
White7375787577378
Black001001
Asian100102
Other010102
Missing8534525
Use of neuroleptics
Use of neuroleptics(Participants)PlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BIDTotal
Yes3131323132157
No5150505050251
CYP2D6 genotype
CYP2D6 genotype(Participants)PlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BIDTotal
Poor metaboliser1542416
Extensive metaboliser7270707469355
Intermediate metaboliser8585935
Ultra-rapid metaboliser110002
Number of Cytosine-Adenosine-Guanine (CAG) Repeats
Number of Cytosine-Adenosine-Guanine (CAG) Repeats(Number of CAG repeats)PlaceboPridopidine 45 mg BIDPridopidine 67.5 mg BIDPridopidine 90 mg BIDPridopidine 112.5 mg BIDTotal
Mean44.4 ± 3.2344.1 ± 4.1245.0 ± 4.7344.5 ± 4.9045.3 ± 3.6644.7 ± 4.18
08

Study locations

58 sites
  • Investigational Site 12199
    La Jolla, California, United States
  • Investigational Site 12204
    Los Angeles, California, United States
  • Investigational Site 12201
    Englewood, Colorado, United States
  • Investigational Site 12196
    Washington, District of Columbia, United States
  • Investigational Site 12207
    Chicago, Illinois, United States
  • Investigational Site 12202
    Baltimore, Maryland, United States
  • Investigational Site 12206
    Baltimore, Maryland, United States
  • Investigational Site 12200
    Manhasset, New York, United States
  • Investigational Site 12203
    New York, New York, United States
  • Investigational Site 12198
    Rochester, New York, United States
  • Investigational Site 12211
    Winston-Salem, North Carolina, United States
  • Investigational Site 12205
    Cincinnati, Ohio, United States
  • Investigational Site 12209
    Pittsburgh, Pennsylvania, United States
  • Investigational Site 12208
    Salt Lake City, Utah, United States
  • Investigational Site 12210
    Richmond, Virginia, United States
  • Investigational Site 12197
    Kirkland, Washington, United States
  • Investigational Site 78055
    Caulfield South, Australia
  • Investigational Site 78056
    Kew, Australia
  • Investigational Site 78058
    Subiaco, Australia
  • Investigational Site 78057
    Westmead, Australia
  • Investigational Site 33021
    Innsbruck, Austria
  • Investigational Site 33027
    Wien, Austria
  • Investigational Site 11035
    Vancouver, British Columbia, Canada
  • Investigational Site 11037
    Ottawa, Ontario, Canada
  • Investigational Site 11036
    Toronto, Ontario, Canada
  • Investigational Site 39028
    Aarhus, Denmark
  • Investigational Site 39027
    Copenhagen, Denmark
  • Investigational Site 35123
    Angers cedex 9, France
  • Investigational Site 35122
    Creteil, France
  • Investigational Site 35125
    Lille, France
  • Investigational Site 35124
    Marseille Cedex 5, France
  • Investigational Site 35121
    Salouel, France
  • Investigational Site 35165
    Toulouse, France
  • Investigational Site 32408
    Berlin, Germany
  • Investigational Site 32410
    Bochum, Germany
  • Investigational Site 32409
    Muenster, Germany
  • Investigational Site 32407
    Ulm, Germany
  • Investigational Site 30083
    Firenze, Italy
  • Investigational Site 30080
    Milano, Italy
  • Investigational Site 30082
    Napoli, Italy
  • Investigational Site 30081
    Pozzilli, Italy
  • Investigational Site 30084
    San Giovanni Rotondo, Italy
  • Investigational Site 38059
    Leiden, Netherlands
  • Investigational Site 53150
    Gdansk, Poland
  • Investigational Site 53149
    Krakow, Poland
  • Investigational Site 53148
    Poznan, Poland
  • Investigational Site 53151
    Warsaw, Poland
  • Investigational Site 50215
    Kazan, Russian Federation
  • Investigational Site 50213
    Moscow, Russian Federation
  • Investigational Site 50214
    Nizhny Novgorod, Russian Federation
  • Investigational Site 34058
    Birmingham, United Kingdom
  • Investigational Site 34054
    Cambridge, United Kingdom
  • Investigational Site 34059
    Cardiff, United Kingdom
  • Investigational Site 34056
    Headington, United Kingdom
  • Investigational Site 34060
    London, United Kingdom
  • Investigational Site 34055
    Manchester, United Kingdom
  • Investigational Site 34061
    Newcastle-Upon-Tyne, United Kingdom
  • Investigational Site 34057
    Sheffield, United Kingdom
09

References and documents

Publications

  • McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. J Huntingtons Dis. 2020;9(4):371-380. doi: 10.3233/JHD-200440. PubMed 33164941 ↗
  • Rodrigues FB, Quinn L, Wild EJ. Huntington's Disease Clinical Trials Corner: January 2019. J Huntingtons Dis. 2019;8(1):115-125. doi: 10.3233/JHD-190001. PubMed 30776019 ↗
  • Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15. PubMed 30563778 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Dec 2015, 21 months.

Results were first posted in Jul 2021, 5 years 7 months after primary completion. A results delay was requested in May 2018.

Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 10, 2013
StartActual
Feb 28, 2014
Primary completionActual
Dec 16, 2015
CompletionActual
Jul 7, 2016
Results delay requested
May 8, 2018
Results first posted
Jul 19, 2021
Last update
Jul 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02006472
Lead sponsor
Prilenia
Collaborators
European Huntington's Disease Network, Huntington Study Group
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Feb 28, 2014
Primary completion
Dec 16, 2015
Completion
Jul 7, 2016
Results posted
Jul 19, 2021
Last update
Jul 19, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion